[1] JOHNSON PC, ABRAMSON JS.Engineered T cells: CAR T cell therapy and beyond[J]. Curr Oncol Rep, 2022, 24(1): 23-31. [2] HOSEN N.CAR T cell therapy[J]. Immunol Med, 2021, 44(2): 69-73. [3] YANG X, WANG GX, ZHOU JF.CAR T cell therapy for hematological malignancie[J]. Curr Med Sci, 2019, 39(6): 874-882. [4] QUALLS D, SALLES G.Optimizing CAR T cell therapy in lymphoma[J]. Hematol Oncol, 2021, 39(1): 104-112. [5] BAO BY, TANG GG, WANG XW, et al.Research progress on new anti-tumor immunotherapy drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2021,18(8):719-724. [6] LANDRY K, THOMAS AA.Neurological complications of CAR T cell therapy[J]. Curr Oncol Rep, 2020, 22(8): 83. [7] SAKODA Y, TAMADA K.Chimeric antigen receptor (CAR)-T cell therapy[J]. Nihon Rinsho, 2017, 75(2): 281-287. [8] ZHANG HM, ZHANG J.Grading and management of toxicities in chimeric antigen receptor T cell therapy[J]. China Cancer(中国肿瘤), 2019, 28(4): 301-307. [9] WU C, JIANG JT.Toxic adverse reactions of CAR-T cellular immunotherapy for the patients with carcinoma and its clinical strategies[J]. Chinese Journal of Cancer Biotherapy(中国肿瘤生物治疗杂志), 2016, 23(6): 745-750. [10] ANWER F, SHAUKAT AA, ZAHID U, et al.Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review[J]. Immunotherapy, 2017, 9(2): 123-130. [11] LI YR, YANG C, LIU WD, et al.Seventy-three cases of suspected unexpected serious adverse reactions reports with chimeric antigen receptor T-cell therapy products[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(9): 600-606. [12] National Food and Drug Administration.Technical Guidelines for Research and Evaluation of Cell Therapy Products (Trial) [EB/OL].(2017-12-22)[2022-04-20]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=452c529b299638297210fe4a1294eb31. [13] MENG SF, HUO Y, HOU TT, et al.Technical considerations on the quality control and nonclinical research for CAR-T cell therapy products[J]. Chinese Pharmaceutical Affairs(中国药事), 2018, 32(6): 829-852. [14] Li YH, HUO Y, YU L, et al.Quality control and nonclinical research on CAR-T cell products: general principles and key issues[J]. Engineering, 2019, 5(1): 263-283. [15] SIEGLER EL, WANG P.Preclinical models in chimeric antigen receptor-engineered T-cell therapy[J]. Hum Gene Ther, 2018, 29(5): 534-546. [16] WEGNER A.Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities[J]. Immunotherapy, 2017, 9(8): 669-680. [17] WU Y, XU R, JIA K, et al.The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: a systematic review and meta-analysis[J]. PLoS One, 2017, 12(11): e187902. [18] HOLZAPFEL BM, WAGNER F, THIBAUDEAU L, et al.Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering[J]. Stem Cells, 2015, 33(6): 1696-1704. [19] KUNKELE A, TARASEVICIUTE A, FINN LS, et al.Preclinical assessment of CD171-directed CAR-T cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility[J]. Clin Cancer Res, 2017, 23(2):466-477. [20] KUMARI R, OUYANG X, WANG J, et al.Preclinical pharmacology modeling of chimeric antigen receptor T therapies[J]. Curr Opin Pharmacol, 2021, 61: 49-61. [21] HUANG Y, HOU TT, HUO Y.Overview of the development and application of animal models in non-clinical studies of CAR-T cell therapy products[J]. Chinese Pharmaceutical Affairs(中国药事), 2018, 32(7): 886-892. [22] TSUKAHARA T, OHMINE K, YAMAMOTO C, et al.CD19 target engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models[J]. Biochemical & Biophysical Research Communications, 2013, 438(1): 84-89. [23] HOU TT, HUANG Y, HUO Y.Considerations of non-clinical pharmacodynamic study of CAR-T cell therapy products[J]. Chinese Pharmaceutical Affairs(中国药事), 2018, 32(9): 1232-1238. [24] TAMMANA S, XIN H, WONG M, et al.4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies[J]. Human Gene Therapy, 2010, 21(1): 75-86. [25] HERMANSON D, BARNETT BE, RENGARAJAN S, et al.Abstract 3759: Piggy bac-manufactured anti-BCMA centyrin-based CAR-T therapeutic exhibits improved potency and durability[J]. Cancer Res, 2017, 77(13): 3759-3759. [26] WANG F, WANG Z, WANG F, et al.Comparative strategies for stem cell biodistribution in a preclinical study[J]. Acta Pharmacol Sin, 2019, 41(4): 572-580. [27] GARITAONANDIA I, GONZALEZ R, CHRISTIANSEN-WEBER T, et al.Neural stem cell tumorigenicity and biodistribution assessment for phase Ⅰ clinical trial in Parkinson's disease[J]. Sci Rep, 2016, 6: 34478. [28] SUGIMOTO H, CHEN S, MINEMBE JP, et al.Insights on droplet digital PCR-based cellular kinetics and biodistribution assay support for CAR-T cell therapy[J]. AAPS J, 2021, 23(2): 36. |